Core Insights - Neuronetics, Inc. plans to release its third quarter 2025 financial and operating results on November 4, 2025, before market open, followed by a conference call at 8:30 a.m. Eastern Time [1] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology, particularly the NeuroStar® Advanced Therapy, which is a leading provider of Transcranial Magnetic Stimulation (TMS) [3] - The company operates Greenbrook TMS Inc. treatment centers across the U.S., offering NeuroStar Advanced Therapy for Major Depressive Disorder (MDD) and other mental health conditions [3] - NeuroStar Advanced Therapy has delivered over 7.6 million treatments and is supported by the largest clinical data set for TMS treatments for depression, including the world's largest depression outcomes registry [3] Treatment Offerings - NeuroStar Advanced Therapy is FDA-cleared for adults with MDD and is also indicated for adolescents aged 15-21 as an adjunct treatment [4] - Greenbrook treatment centers provide SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression (TRD) and for adults with MDD exhibiting acute suicidal ideation [3][4] - Greenbrook has administered over 1.8 million treatments to more than 55,000 patients suffering from depression [3]